- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01735617
Étude pilote pour caractériser et examiner la pharmacocinétique et l'efficacité de Chronocort® chez les adultes atteints d'HCS
Une étude pilote de phase 2 pour caractériser et examiner la pharmacocinétique et la réponse des biomarqueurs de la maladie de Chronocort® chez les adultes atteints d'hyperplasie congénitale des surrénales
The purpose of this study is to gather safety and effectiveness information about a new formulation of Hydrocortisone (Chronocort®) used to treat patients with a disease called congenital adrenal hyperplasia (CAH). Hydrocortisone is the man-made version of the hormone cortisol, which is released in the body following a regular daily pattern. The objective of the study is to measure the levels of hydrocortisone that are absorbed into the bloodstream once Chronocort® is taken and what affects it has on other hormones in the body. Since Chronocort® is anticipated to mimic the same release pattern of cortisol in the body, it is hoped that patients with CAH will be treated more effectively to manage their disease.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
This study is a Phase 2 pilot study to characterize and examine the pharmacokinetics and efficacy profile of Chronocort® in adults with congenital adrenal hyperplasia (CAH). It is designed as a two-part, single cohort, open label, multiple dose Phase 2 pilot study to: (Part A) characterize and examine the pharmacokinetics (PK) and disease bio-marker behavior following short-term dosing with Chronocort®; and to (Part B) examine the disease control after six months dose titration with Chronocort® in adults with CAH.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892-1932
- National Institutes of Health Clinical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Known CAH due to 21-hydroxylase deficiency (classic CAH) based on hormonal and genetic testing currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone on a stable dosage for a minimum of 3 months.
- Male or female patients aged 18 and above.
- Provision of signed written informed consent.
- Good general health.
- Females of childbearing potential must have a negative pregnancy test initially and at all visits. Females who are engaging in sexual intercourse must be using a medically acceptable method of contraception (as defined in the protocol, section 10.5).
- Plasma renin activity must be within the clinically acceptable range at screening (less than 1.5 times upper normal range).
Exclusion Criteria:
- Co-morbid condition requiring daily administration of a medication that induces hepatic enzymes or interferes with the metabolism of glucocorticoids.
- Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the normal range or elevated liver function tests (ALT or AST) > 2 times the upper limits of normal.
- Females who are pregnant or lactating.
- Women taking an estrogen-containing oral contraceptive pill and who have taken it within 6 weeks of recruitment.
- Patients taking spironolactone.
- Patients on inhaled or oral steroids apart from treatment for CAH.
- Patients with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the trial.
- Participation in another clinical trial of an investigational or licensed drug or device within the 3 months prior to inclusion in this study.
- Patients with history of bilateral adrenalectomy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Hydrocortisone Modified Release Capsules
Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response |
Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
Délai: 24 hours
|
The maximum plasma concentration (Cmax) of chronocort |
24 hours
|
|
Pharmacokinetic Profile (AUC0-24) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
Délai: 24 hours (at 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)
|
Area under the curve (AUC) from 0 to 24 hours (sampling occurs at the following timepoints: 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs) |
24 hours (at 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)
|
|
Pharmacokinetic Profile (Tmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
Délai: 24 hours
|
Time to maximum plasma concentration (tmax) |
24 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The Percentage of Patients With 17-OHP and Androstenedione Levels at 0700h Within Proposed Optimal Ranges Whilst on Chronocort and Whilst on Standard Therapy (at Baseline)
Délai: Specific time point (0700hrs)
|
Proposed optimal ranges of 17-OHP: 300-1200ng/dl Proposed optimal ranges of androstenedione: 40-150ng.dl for males and 30-200ng/dl for females |
Specific time point (0700hrs)
|
|
17-OHP Levels at 0700h, 1700h and 2300h
Délai: Specified time points (0700h, 1700h and 2300h)
|
17-OHP levels at 0700h, 1700h and 2300h |
Specified time points (0700h, 1700h and 2300h)
|
|
Androstenedione Levels at 0700h, 1700h and 2300h
Délai: Specified time points (0700h, 1700h and 2300h)
|
Androstenedione levels at 0700h, 1700h and 2300h |
Specified time points (0700h, 1700h and 2300h)
|
|
ACTH Levels at 0700h, 1700h and 2300h
Délai: Specified time points (0700h, 1700h and 2300h)
|
ACTH levels at 0700h, 1700h and 2300h |
Specified time points (0700h, 1700h and 2300h)
|
|
AUC Values (Nmol*h/L) for Androstenedione
Délai: Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
|
AUC values (nmol*h/L) for Androstenedione for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h |
Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
|
|
AUC Values (Nmol*h/L) for 17-OHP
Délai: Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
|
AUC values (nmol*h/L) for 17-OHP for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h |
Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
|
|
AUC Values (Pmol*h/L) for ACTH
Délai: Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
|
AUC values (pmol*h/L) for ACTH for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h |
Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Deborah P Merke, BS, MS, MD, National Institutes of Health Clinical Center (CC)
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Métabolisme, erreurs innées
- Maladies génétiques, innées
- Maladies métaboliques
- Troubles gonadiques
- Anomalies congénitales
- Maladies des glandes surrénales
- Troubles du développement sexuel
- Anomalies urogénitales
- Métabolisme des stéroïdes, erreurs innées
- Syndrome surrénogénital
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies nutritionnelles et métaboliques
- Hyperplasie surrénalienne, congénitale
- Insuffisance surrénalienne
- Maladies du système endocrinien
Autres numéros d'identification d'étude
- DIUR-003
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .